JP2016528304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528304A5 JP2016528304A5 JP2016537780A JP2016537780A JP2016528304A5 JP 2016528304 A5 JP2016528304 A5 JP 2016528304A5 JP 2016537780 A JP2016537780 A JP 2016537780A JP 2016537780 A JP2016537780 A JP 2016537780A JP 2016528304 A5 JP2016528304 A5 JP 2016528304A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- pdgf
- iib
- diastereomeric excess
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 69
- 238000000034 method Methods 0.000 claims 38
- 239000000427 antigen Substances 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 10
- 101150029707 ERBB2 gene Proteins 0.000 claims 9
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 8
- -1 PDGF-B Proteins 0.000 claims 8
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 7
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 7
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 6
- 102100023123 Mucin-16 Human genes 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims 4
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims 4
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 4
- 101800000504 3C-like protease Proteins 0.000 claims 4
- 102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 claims 4
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 claims 4
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 4
- 102000036365 BRCA1 Human genes 0.000 claims 4
- 108700020463 BRCA1 Proteins 0.000 claims 4
- 101150072950 BRCA1 gene Proteins 0.000 claims 4
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 claims 4
- 102000015735 Beta-catenin Human genes 0.000 claims 4
- 108060000903 Beta-catenin Proteins 0.000 claims 4
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims 4
- 101150013553 CD40 gene Proteins 0.000 claims 4
- 101800001318 Capsid protein VP4 Proteins 0.000 claims 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 4
- 102000004091 Caspase-8 Human genes 0.000 claims 4
- 108090000538 Caspase-8 Proteins 0.000 claims 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 4
- 108010060385 Cyclin B1 Proteins 0.000 claims 4
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 4
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 4
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 claims 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 4
- 108010055196 EphA2 Receptor Proteins 0.000 claims 4
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 4
- 102100035139 Folate receptor alpha Human genes 0.000 claims 4
- 102000003817 Fos-related antigen 1 Human genes 0.000 claims 4
- 108090000123 Fos-related antigen 1 Proteins 0.000 claims 4
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 claims 4
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 claims 4
- 102000010956 Glypican Human genes 0.000 claims 4
- 108050001154 Glypican Proteins 0.000 claims 4
- 108050007237 Glypican-3 Proteins 0.000 claims 4
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 4
- 101000936083 Homo sapiens Baculoviral IAP repeat-containing protein 7 Proteins 0.000 claims 4
- 101000912622 Homo sapiens C-type lectin domain family 12 member A Proteins 0.000 claims 4
- 101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 claims 4
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 4
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 4
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 4
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 claims 4
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 4
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 4
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 4
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims 4
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 claims 4
- 101001131670 Homo sapiens PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims 4
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 claims 4
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 claims 4
- 101000691463 Homo sapiens Placenta-specific protein 1 Proteins 0.000 claims 4
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 4
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 claims 4
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims 4
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 claims 4
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 claims 4
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 4
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims 4
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 4
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims 4
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 claims 4
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 4
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 4
- 102000003735 Mesothelin Human genes 0.000 claims 4
- 108090000015 Mesothelin Proteins 0.000 claims 4
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims 4
- 102000036673 PRAME Human genes 0.000 claims 4
- 108060006580 PRAME Proteins 0.000 claims 4
- 102100040891 Paired box protein Pax-3 Human genes 0.000 claims 4
- 102100037504 Paired box protein Pax-5 Human genes 0.000 claims 4
- 102100026181 Placenta-specific protein 1 Human genes 0.000 claims 4
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims 4
- 102100040681 Platelet-derived growth factor C Human genes 0.000 claims 4
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 4
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 claims 4
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 4
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 claims 4
- 102100029000 Prolactin receptor Human genes 0.000 claims 4
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims 4
- 102100037421 Regulator of G-protein signaling 5 Human genes 0.000 claims 4
- 101710140403 Regulator of G-protein signaling 5 Proteins 0.000 claims 4
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 claims 4
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims 4
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 claims 4
- 101710185775 Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 claims 4
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 claims 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 claims 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 4
- 102000003425 Tyrosinase Human genes 0.000 claims 4
- 108060008724 Tyrosinase Proteins 0.000 claims 4
- 102000015979 Uroplakin-3 Human genes 0.000 claims 4
- 108050004262 Uroplakin-3 Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 4
- 239000003960 organic solvent Substances 0.000 claims 4
- 101800000607 p15 Proteins 0.000 claims 4
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims 4
- 108010017992 platelet-derived growth factor C Proteins 0.000 claims 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 4
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000016914 ras Proteins Human genes 0.000 claims 4
- 108010014186 ras Proteins Proteins 0.000 claims 4
- 101150047061 tag-72 gene Proteins 0.000 claims 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 4
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims 3
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 3
- 108700012439 CA9 Proteins 0.000 claims 3
- 102100039554 Galectin-8 Human genes 0.000 claims 3
- 101000608769 Homo sapiens Galectin-8 Proteins 0.000 claims 3
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 3
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 3
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims 3
- 102100040682 Platelet-derived growth factor D Human genes 0.000 claims 3
- 101710170209 Platelet-derived growth factor D Proteins 0.000 claims 3
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims 3
- 108010002687 Survivin Proteins 0.000 claims 3
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims 3
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 claims 2
- 101710155955 U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 claims 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960004424 carbon dioxide Drugs 0.000 claims 1
- 235000011089 carbon dioxide Nutrition 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 0 CCC(N(C(C)=O)OC(C1CCC(CN(C[C@](C2)SCCC(N(C)[C@@](C)C(O[C@@](CC(N(C)c(cc(CC(C)=CC=CC[C@@](*)(C[C@@]([C@@](C)[C@@]3C)O4)NC4=O)cc4OC)c4Cl)=O)[C@]3(C)O)=O)=O)C2=O)CC1)=O)=O Chemical compound CCC(N(C(C)=O)OC(C1CCC(CN(C[C@](C2)SCCC(N(C)[C@@](C)C(O[C@@](CC(N(C)c(cc(CC(C)=CC=CC[C@@](*)(C[C@@]([C@@](C)[C@@]3C)O4)NC4=O)cc4OC)c4Cl)=O)[C@]3(C)O)=O)=O)C2=O)CC1)=O)=O 0.000 description 2
- KYEACNNYFNZCST-UHFFFAOYSA-N CN(C(CC1)=O)C1=O Chemical compound CN(C(CC1)=O)C1=O KYEACNNYFNZCST-UHFFFAOYSA-N 0.000 description 1
- ZOHMLMSFANJYJX-IKYRSUNISA-N C[C@@H](C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C1)(N2)O)OC)cc3OC)c3Cl)=O)C(C)(C)C[C@H](C)[C@H](C)[C@H]1OC2=O)=O)N(C)C(CCS[C@@H](CC(N1C[C@H](CC2)CC[C@@H]2C(NC)=O)=O)C1=O)=O Chemical compound C[C@@H](C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C1)(N2)O)OC)cc3OC)c3Cl)=O)C(C)(C)C[C@H](C)[C@H](C)[C@H]1OC2=O)=O)N(C)C(CCS[C@@H](CC(N1C[C@H](CC2)CC[C@@H]2C(NC)=O)=O)C1=O)=O ZOHMLMSFANJYJX-IKYRSUNISA-N 0.000 description 1
- KULSTBXBZKPZTR-PZGBMNGCSA-N C[C@@H](C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C1)(N2)O)OC)cc3OC)c3Cl)=O)C(C)(C)[C@@H](C)[C@H](C)[C@H]1OC2=O)=O)N(C)C(CCS[C@@H](CC(N1CC(CC2)CCC2C(ON(C(CC2)=O)C2=O)=O)=O)C1=O)=O Chemical compound C[C@@H](C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C1)(N2)O)OC)cc3OC)c3Cl)=O)C(C)(C)[C@@H](C)[C@H](C)[C@H]1OC2=O)=O)N(C)C(CCS[C@@H](CC(N1CC(CC2)CCC2C(ON(C(CC2)=O)C2=O)=O)=O)C1=O)=O KULSTBXBZKPZTR-PZGBMNGCSA-N 0.000 description 1
- UFBDAXMBTLETBL-JSBZNDHUSA-N C[C@@H](C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C[C@H](C)C[C@@H]1C)(NC(O)=O)O)OC)cc2[O](C)C)c2Cl)=O)[C@]1(C)O)=O)N(C)C(CCS[C@@H](CC(N1C[C@H](CC2)CC[C@@H]2C(NC)=O)=O)C1=O)=O Chemical compound C[C@@H](C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C[C@H](C)C[C@@H]1C)(NC(O)=O)O)OC)cc2[O](C)C)c2Cl)=O)[C@]1(C)O)=O)N(C)C(CCS[C@@H](CC(N1C[C@H](CC2)CC[C@@H]2C(NC)=O)=O)C1=O)=O UFBDAXMBTLETBL-JSBZNDHUSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361869954P | 2013-08-26 | 2013-08-26 | |
| US61/869,954 | 2013-08-26 | ||
| US201461934313P | 2014-01-31 | 2014-01-31 | |
| US61/934,313 | 2014-01-31 | ||
| PCT/US2014/052757 WO2015031396A1 (en) | 2013-08-26 | 2014-08-26 | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016528304A JP2016528304A (ja) | 2016-09-15 |
| JP2016528304A5 true JP2016528304A5 (OSRAM) | 2017-10-12 |
| JP6608823B2 JP6608823B2 (ja) | 2019-11-20 |
Family
ID=51542449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537780A Active JP6608823B2 (ja) | 2013-08-26 | 2014-08-26 | マクロライドジアステレオマーを含む医薬組成物、その合成方法、及び治療上の使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20160354482A1 (OSRAM) |
| EP (1) | EP3038624B1 (OSRAM) |
| JP (1) | JP6608823B2 (OSRAM) |
| KR (1) | KR102252925B1 (OSRAM) |
| CN (1) | CN105530942B (OSRAM) |
| AU (1) | AU2014311361B2 (OSRAM) |
| BR (1) | BR112016004023A2 (OSRAM) |
| CA (1) | CA2921412C (OSRAM) |
| CL (1) | CL2016000408A1 (OSRAM) |
| EA (1) | EA038192B1 (OSRAM) |
| ES (1) | ES2989322T3 (OSRAM) |
| IL (1) | IL244203B (OSRAM) |
| MX (1) | MX373528B (OSRAM) |
| PH (1) | PH12016500380A1 (OSRAM) |
| SG (1) | SG11201601230RA (OSRAM) |
| WO (1) | WO2015031396A1 (OSRAM) |
| ZA (1) | ZA201601534B (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3964237B1 (en) | 2013-03-15 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| KR102252925B1 (ko) | 2013-08-26 | 2021-05-18 | 리제너론 파마슈티칼스 인코포레이티드 | 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도 |
| KR20240142591A (ko) | 2015-03-27 | 2024-09-30 | 리제너론 파아마슈티컬스, 인크. | 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법 |
| MY189159A (en) | 2015-07-06 | 2022-01-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| MY198605A (en) | 2016-01-25 | 2023-09-08 | Regeneron Pharma | Maytansinoid derivatives conjugates thereof, and methods of use |
| WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| US10738130B2 (en) | 2016-09-23 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof |
| MA46417A (fr) | 2016-09-23 | 2019-07-31 | Regeneron Pharma | Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations |
| TWI782930B (zh) * | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| EP3548514A1 (en) | 2016-11-29 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Methods of treating prlr positive breast cancer |
| KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| ES3065816T3 (en) | 2017-06-07 | 2026-05-08 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| IL313068A (en) | 2017-11-07 | 2024-07-01 | Regeneron Pharma | Hydrophilic linkers for antibody drug conjugates |
| CN112074538B (zh) | 2018-04-30 | 2024-10-18 | 瑞泽恩制药公司 | 结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途 |
| BR112020023145A2 (pt) | 2018-05-17 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto |
| CA3111147A1 (en) * | 2018-08-31 | 2020-03-05 | Osteoanalgesia Llc | Diastereomeric conjugate compositions and methods of making and using same |
| MX2021010114A (es) | 2019-02-21 | 2021-12-10 | Regeneron Pharma | Métodos para tratar el cáncer ocular mediante el uso de anticuerpos anti-met y moléculas de unión a antígeno bispecíficas que se unen a met. |
| JP7750828B2 (ja) | 2019-09-16 | 2025-10-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質 |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| EP4058024A1 (en) | 2019-11-15 | 2022-09-21 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
| IL295312A (en) | 2020-02-28 | 2022-10-01 | Regeneron Pharma | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
| JP2023521885A (ja) | 2020-04-16 | 2023-05-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ディールス－アルダーコンジュゲーション方法 |
| US12605459B2 (en) | 2020-07-13 | 2026-04-21 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| CA3190569A1 (en) | 2020-10-22 | 2022-04-28 | Christopher Daly | Anti-fgfr2 antibodies and methods of use thereof |
| AU2021377185A1 (en) | 2020-11-10 | 2023-06-08 | Regeneron Pharmaceuticals, Inc. | Selenium antibody conjugates |
| CN115215780B (zh) * | 2022-04-22 | 2023-08-08 | 上海格苓凯生物科技有限公司 | 一种利用n,n-二琥珀酰亚胺基碳酸酯制备异双功能交联剂smcc的方法 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| US7736644B2 (en) | 2003-06-27 | 2010-06-15 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| AU2005316844A1 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| PL1819359T3 (pl) | 2004-12-09 | 2015-08-31 | Janssen Biotech Inc | Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| AU2007308792B2 (en) | 2006-10-27 | 2013-01-24 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| TW200902554A (en) | 2007-05-08 | 2009-01-16 | Genentech Inc | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
| ES2731432T3 (es) | 2007-05-23 | 2019-11-15 | Ventana Med Syst Inc | Transportadores poliméricos para inmunohistoquímica e hibridación in situ |
| NZ587706A (en) * | 2008-03-18 | 2012-12-21 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| RU2487877C2 (ru) | 2008-04-30 | 2013-07-20 | Иммьюноджен, Инк. | Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры) |
| WO2010010324A1 (en) | 2008-07-21 | 2010-01-28 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| WO2011018613A1 (en) | 2009-08-10 | 2011-02-17 | Ucl Business Plc | Functionalisation of solid substrates |
| UY32913A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero |
| UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
| JP2013506709A (ja) * | 2009-10-06 | 2013-02-28 | イミュノジェン・インコーポレーテッド | 有効なコンジュゲートおよび親水性リンカー |
| US8501692B2 (en) | 2009-12-14 | 2013-08-06 | The Regents Of The University Of Michigan | Compositions and methods for altering cocaine esterase activity |
| WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2012005982A2 (en) | 2010-07-06 | 2012-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Reporter for rna polymerase ii termination |
| KR102306967B1 (ko) | 2010-08-02 | 2021-10-01 | 리제너론 파아마슈티컬스, 인크. | Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스 |
| WO2012028579A1 (de) | 2010-09-01 | 2012-03-08 | Bayer Cropscience Ag | N-(tetrazol-5-yl)- und n-(triazol-5-yl)arylcarbonsäureamide und ihre verwendung als herbizide |
| CN103328505B (zh) | 2010-10-29 | 2015-12-02 | 伊缪诺金公司 | 非拮抗性egfr结合分子及其免疫偶联物 |
| JP2013542958A (ja) | 2010-11-03 | 2013-11-28 | イミュノジェン・インコーポレーテッド | アンサマイトシン誘導体を含む細胞傷害性剤 |
| EP2709666B1 (en) | 2011-05-16 | 2021-07-14 | Koninklijke Philips N.V. | Bio-orthogonal drug activation |
| EP2714685B1 (en) | 2011-05-27 | 2016-10-19 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| MX350954B (es) | 2011-06-21 | 2017-09-26 | Immunogen Inc | Derivados de maitansinoides novedosos con enlazador de peptido y conjugados de estos. |
| MX358757B (es) | 2011-10-14 | 2018-09-03 | Seattle Genetics Inc | Pirrolobenzodiazepinas y conjugados dirigidos. |
| SG11201401021TA (en) | 2011-10-14 | 2014-08-28 | Spirogen Sarl | Pyrrolobenzodiazepines |
| US9526798B2 (en) | 2011-10-14 | 2016-12-27 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| US9102704B2 (en) | 2011-10-14 | 2015-08-11 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| AU2012348017A1 (en) | 2011-12-05 | 2014-07-03 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
| GB201210770D0 (en) | 2012-06-18 | 2012-08-01 | Polytherics Ltd | Novel conjugation reagents |
| SG11201407600UA (en) | 2012-06-19 | 2014-12-30 | Polytherics Ltd | Novel process for preparation of antibody conjugates and novel antibody conjugates |
| ES2659270T5 (en) | 2012-10-23 | 2026-02-11 | Synaffix Bv | Modified antibody, antibody-conjugate and process for the preparation thereof |
| NO2789793T3 (OSRAM) | 2012-10-24 | 2018-01-27 | ||
| AU2012395148B2 (en) | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| CN103254213B (zh) | 2012-12-21 | 2015-02-25 | 百奥泰生物科技(广州)有限公司 | 类美登素酯的制备方法及用于所述方法的组合物 |
| CN104650113A (zh) | 2012-12-21 | 2015-05-27 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
| EP3964237B1 (en) | 2013-03-15 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| CN103254311B (zh) * | 2013-05-09 | 2015-05-13 | 齐鲁制药有限公司 | 一种制备抗体-美登素类生物碱药物偶联物的方法 |
| WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| SG10201708143QA (en) | 2013-06-06 | 2017-11-29 | Pf Medicament | Anti-c10orf54 antibodies and uses thereof |
| WO2014197854A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
| US20140363454A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-Drug Conjugates, Compositions and Methods of Use |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| KR102252925B1 (ko) | 2013-08-26 | 2021-05-18 | 리제너론 파마슈티칼스 인코포레이티드 | 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도 |
| CN105744935B (zh) | 2013-11-27 | 2022-09-30 | 雷德伍德生物科技股份有限公司 | 肼基-吡咯并化合物及用于生成缀合物的方法 |
| CN105793268B (zh) | 2013-12-02 | 2019-03-15 | 香港浸会大学 | 具有两个稠合大环的抗癌性美登木素类化合物 |
| WO2015187596A2 (en) | 2014-06-02 | 2015-12-10 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
| KR20240142591A (ko) | 2015-03-27 | 2024-09-30 | 리제너론 파아마슈티컬스, 인크. | 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법 |
| MY198605A (en) | 2016-01-25 | 2023-09-08 | Regeneron Pharma | Maytansinoid derivatives conjugates thereof, and methods of use |
-
2014
- 2014-08-26 KR KR1020167008038A patent/KR102252925B1/ko active Active
- 2014-08-26 AU AU2014311361A patent/AU2014311361B2/en active Active
- 2014-08-26 MX MX2016002149A patent/MX373528B/es active IP Right Grant
- 2014-08-26 BR BR112016004023A patent/BR112016004023A2/pt not_active Application Discontinuation
- 2014-08-26 SG SG11201601230RA patent/SG11201601230RA/en unknown
- 2014-08-26 ES ES14766580T patent/ES2989322T3/es active Active
- 2014-08-26 CA CA2921412A patent/CA2921412C/en active Active
- 2014-08-26 CN CN201480047607.3A patent/CN105530942B/zh active Active
- 2014-08-26 EA EA201600191A patent/EA038192B1/ru unknown
- 2014-08-26 JP JP2016537780A patent/JP6608823B2/ja active Active
- 2014-08-26 US US14/913,965 patent/US20160354482A1/en not_active Abandoned
- 2014-08-26 WO PCT/US2014/052757 patent/WO2015031396A1/en not_active Ceased
- 2014-08-26 EP EP14766580.6A patent/EP3038624B1/en active Active
-
2016
- 2016-02-21 IL IL244203A patent/IL244203B/en active IP Right Grant
- 2016-02-23 CL CL2016000408A patent/CL2016000408A1/es unknown
- 2016-02-26 PH PH12016500380A patent/PH12016500380A1/en unknown
- 2016-03-04 ZA ZA2016/01534A patent/ZA201601534B/en unknown
-
2018
- 2018-11-13 US US16/189,925 patent/US11596635B2/en active Active
-
2022
- 2022-12-22 US US18/145,811 patent/US20230321109A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502746A5 (OSRAM) | ||
| TWI869913B (zh) | 吡啶并[4,3-d]嘧啶化合物 | |
| CN114728966B (zh) | 作为mnk抑制剂的吡咯并三嗪类化合物 | |
| KR102252925B1 (ko) | 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도 | |
| JP2018537516A5 (OSRAM) | ||
| IL263616B1 (en) | Antibody adjuvant conjugates | |
| JP2018524358A5 (OSRAM) | ||
| JP2017095457A5 (OSRAM) | ||
| JP2024533356A5 (OSRAM) | ||
| JP2019501204A5 (OSRAM) | ||
| JP2012153722A5 (OSRAM) | ||
| JP2017510661A5 (OSRAM) | ||
| JP2019502650A5 (ja) | 抗ＥｒｂＢ２抗体−薬物コンジュゲート及びその組成物、そのための調製方法、並びにその使用 | |
| RU2013128361A (ru) | Her2-связывающие белки, меченые комплексом 18f-фторида алюминия и nota | |
| JP2015523326A5 (OSRAM) | ||
| Zhao et al. | Antitumour vaccination via the targeted proteolysis of antigens isolated from tumour lysates | |
| JPWO2020027100A5 (OSRAM) | ||
| JP2016534105A (ja) | ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用 | |
| JP2011520770A5 (OSRAM) | ||
| JP2022512401A5 (OSRAM) | ||
| IL273387B2 (en) | Thylanstatin analogs | |
| PH12022551098A1 (en) | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| CN114190090A (zh) | Shp2抑制剂{6-[(2-氨基-3-氯吡啶-4-基)硫烷基]-3-[(3s,4s)-4-氨基-3-甲基-2-氧杂-8-氮杂螺[4.5]癸烷-8-基]-5-甲基吡嗪-2-基}甲醇的固体形式 | |
| JP2023523083A5 (OSRAM) | ||
| JP2025516596A5 (OSRAM) |